Reversible cardiomyopathy-tachycardiomyopathy in children

dc.contributor.authorArslan, Alev
dc.contributor.authorErdogan, Ilkay
dc.contributor.authorVaran, Birgul
dc.contributor.authorYılmaz, Mustafa
dc.contributor.authorOzin, Mehmet Bülent
dc.contributor.authorTokel, Niyazi Kursad
dc.contributor.pubmedID31990473en_US
dc.date.accessioned2020-07-15T20:16:53Z
dc.date.available2020-07-15T20:16:53Z
dc.date.issued2019
dc.description.abstractTachycardia-induced cardiomyopathy (tachycardiomyopathy) is defined by the presence of a sustained tachycardia that results in left ventricular systolic dysfunction. Restoration of cardiac function is dependent on the control of tachyarrhythmias. We report a series including ten children with tachycardia-induced cardiomyopathy with different etiologies. The medical records of patients with tachycardiomyopathy who were managed in a Pediatric Cardiology Clinic between the years of 2014-2017 were reviewed retrospectively. Ten children (3 female, 7 male) were diagnosed with tachycardiomyopathy. The median age of the patients was 12 years (range: 4-15.8). Five had atrial tachycardia, two had ventricular tachycardia, the others had Mahaim fiber tachycardia, permanent junctional reciprocating tachycardia and atrioventricular reentrant tachycardia. Seven patients had catheter ablation and three patients who had previous heart surgery were treated with antiarrhythmic drugs. Median ejection fraction was 33% (range: 10-48), median left ventricle end-diastolic diameter was 55 mm (range: 30-78). All showed complete recovery with median ejection fraction 60% (range: 55-78). Two patient with severe heart failure required extracorporeal membrane oxygenation support, one of them had ventricular assist device support but the device was removed after successful ablation. After two years this patient required permanent pacemaker implantation due to complete atrioventricular block. Tachycardia-induced cardiomyopathy is a rare and treatable cause of heart failure. Early recognition is critical, aggressive treatment aimed at controlling the arrhythmia results in symptom resolution and recovery of ventricular function.en_US
dc.identifier.endpage559en_US
dc.identifier.issn0041-4301en_US
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85078339762en_US
dc.identifier.startpage552en_US
dc.identifier.urihttp://www.turkishjournalpediatrics.org/uploads/pdf_TJP_2023.pdf
dc.identifier.urihttp://hdl.handle.net/11727/4760
dc.identifier.volume61en_US
dc.identifier.wos000508895200011en_US
dc.language.isoengen_US
dc.relation.isversionof10.24953/turkjped.2019.04.012en_US
dc.relation.journalTURKISH JOURNAL OF PEDIATRICSen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectablationen_US
dc.subjectcardiomyopathyen_US
dc.subjectextracorporeal membrane oxygenationen_US
dc.subjecttachycardiaen_US
dc.titleReversible cardiomyopathy-tachycardiomyopathy in childrenen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
pdf_TJP_2023.pdf
Size:
3.02 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: